Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.16 | N/A | -8.92% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.16 | N/A | -8.92% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions impacting performance. They reiterated their commitment to navigating these challenges.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite current setbacks.
Kodiak Sciences reported a larger-than-expected loss per share, which contributed to a significant drop in stock price by 6.81%. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Management's defensive tone suggests they are facing challenges that could impact growth moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COREWEAVE INC Class A
Nov 10, 2025